{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:33:17Z","timestamp":1786444397289,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The CD6 cell surface glycoprotein is expressed by almost all T cells, a small subset of B cells and a substantial proportion of human natural killer (NK) cells. CD6 has multiple ligands and multiple functional epitopes. It is a component of the immunological synapse, and can positively or negatively influence signal transduction in T cells through complex interactions with multiple kinases and adapter molecules. Antibodies to CD6 are effective in the treatment of autoimmune diseases in experimental systems and in humans. The recent discovery that CD318 (CDCP1), a driver molecule in many cancers, is a ligand for CD6 has prompted investigation of CD6 as a possible new target for immunotherapy of cancer. A monoclonal antibody to CD6 rapidly internalizes CD6 and alters gene expression in CD8+ T cells and NK cells to augment the cytotoxicity of human lymphocytes to human cancer cells from a range of neoplasms. This review, using a question and answer format, describes recent work on anti-CD6 as a candidate immunotherapy for cancer as well as relevant advances in our understanding of other aspects of the biology of CD6, and explores the possibility that this approach could avoid the autoimmune complications that are encountered with checkpoint inhibitor treatment of cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1845422","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:54:25Z","timestamp":1786442065000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy of cancer without induction of autoimmunity \u2013 CD6 as a therapeutic target"],"prefix":"10.3389","volume":"17","author":[{"given":"David A.","family":"Fox","sequence":"first","affiliation":[{"name":"Division of Rheumatology and Program in Translational Immunology, University of Michigan","place":["Ann Arbor, Michigan, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Gurrea-Rubio","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Program in Translational Immunology, University of Michigan","place":["Ann Arbor, Michigan, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxf025","article-title":"CD6: expression during development, apoptosis and selection of human and mouse thymocytes","volume":"14","author":"Singer","year":"2002","journal-title":"Int Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151785","article-title":"CD6 modulates thymocyte selection and peripheral T cell homeostasis","volume":"213","author":"Orta-Mascaro","year":"2016","journal-title":"J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1615253114","article-title":"CD6 as a potential target for treating multiple sclerosis","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jaut.2018.02.004","article-title":"Targeting CD6 for the treatment of experimental autoimmune uveitis","volume":"90","author":"Zhang","year":"2018","journal-title":"J Autoimmun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.41288","article-title":"Attenuation of murine collagen-induced arthritis by targeting CD6","volume":"72","author":"Li","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2013.05.043","article-title":"Identification of functionally relevant phoshorylatable serine clusters in the cytoplasmic region of the human CD6 lymphocyte surface receptor","volume":"587","author":"Bonet","year":"2013","journal-title":"FEBS Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209591200","article-title":"The accessory molecules CD5 and CD6 associate on the membrane of lymphoid T cells","volume":"278","author":"Gimferrer","year":"2003","journal-title":"J Biol Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02994","article-title":"CD6, a rheostat-type signalosome that tunes T cell activation","volume":"9","author":"Goncalves","year":"2018","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4351","article-title":"Extracellular isoforms of CD6 generated by alternative splicing regulate targeting of CD6 to the immunological synapse","volume":"178","author":"Castro","year":"2007","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000322720","article-title":"The CD6 scavenger receptor is differentially expressed on a CD56 natural killer cell subpopulation and contributes to natural killer-derived cytokine and chemokine secretion","volume":"3","author":"Braun","year":"2011","journal-title":"J Innate Immun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145662","article-title":"CD6 is a target for cancer immunotherapy","volume":"6","author":"Ruth","year":"2021","journal-title":"JCI Insight"},{"key":"B12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00262-023-03578-1","article-title":"Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells","volume":"73","author":"Gurrea-Rubio","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201011","article-title":"The T cell CD6 receptor operates a multitask signalosome with opposite functions in T cell activation","volume":"218","author":"Mori","year":"2021","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12964-024-01658-y","article-title":"The CD6 interactome orchestrates ligand-independent T cell inhibitory signaling","volume":"22","author":"Santos","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.142298399","article-title":"CD28 plays a critical role in the segregation of PKC theta within the immunologic synapse","volume":"99","author":"Huang","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adz4203","article-title":"CD318 expression defines a novel subset of human CD8(+) regulatory T cells","volume":"12","author":"Do","year":"2026","journal-title":"Sci Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.6.2213","article-title":"Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand","volume":"181","author":"Bowen","year":"1995","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<329::AID-ANR12>3.0.CO;2-Y","article-title":"Evidence for the expression of a second CD6 ligand by synovial fibroblasts","volume":"43","author":"Joo","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.10.6125","article-title":"Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissues","volume":"173","author":"Saifullah","year":"2004","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1704008114","article-title":"CD318 is a ligand for CD6","volume":"114","author":"Enyindah-Asonye","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiad124","article-title":"CD6 triggers actomyosin cytoskeleton remodeling after binding to its receptor complex","volume":"115","author":"Borjini","year":"2024","journal-title":"J Leukoc Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2174\/1389450116666150316224308","article-title":"Pattern recognition by CD6: a scavenger-like lymphocyte receptor","volume":"17","author":"Sarukhan","year":"2016","journal-title":"Curr Drug Targets"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105078","article-title":"CD6 deficiency impairs early immune response to bacterial sepsis","volume":"25","author":"Catala","year":"2022","journal-title":"iScience"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112225","article-title":"Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: results from an expanded-access program","volume":"134","author":"Falcon Lincheta","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1776254","article-title":"Anti-CD6 mAbs for the treatment of psoriasis","volume":"20","author":"Dogra","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2988-9","article-title":"Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study","volume":"35","author":"Chopra","year":"2016","journal-title":"Clin Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10071-23787","article-title":"Off-label use of itolizumab in patients with COVID-19 ARDS: our clinical experience in a dedicated COVID center","volume":"25","author":"Kumari","year":"2021","journal-title":"Indian J Crit Care Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100626","article-title":"The CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4+ T cell proliferation","volume":"187","author":"Kofler","year":"2011","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/5.7.783","article-title":"Activation of human T cells through CD6: functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein","volume":"5","author":"Bott","year":"1993","journal-title":"Int Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12952","article-title":"CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action","volume":"155","author":"Garner","year":"2018","journal-title":"Immunology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.172914","article-title":"A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disorders","volume":"8","author":"Zhang","year":"2023","journal-title":"JCI Insight"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1845422\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:54:26Z","timestamp":1786442066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1845422\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1845422"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1845422","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1845422"}}